XML 73 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Basic and Diluted Loss Per Share (Tables)
 12 Months Ended
Dec. 31, 2020
Basic and Diluted Loss Per Share  
Schedule of basic and diluted loss per share

 

 

 

 

 

 

 

 

 

 

 

    

Year Ended December 31, 

 

    

2020

    

2019

    

2018

 

 

(USD in thousands, except share amounts and per share amounts)

Loss per share before and after dilution

 

 

 

 

 

  

 

 

  

Net loss attributable to shareholders of Evaxion Biotech A/S

 

$

(15,018)

 

$

(11,195)

 

$

(5,535)

Weighted-average number of ordinary shares outstanding

 

 

15,434,758

 

 

13,892,314

 

 

12,917,016

Loss per share before and after dilution

 

$

(0.97)

 

$

(0.81)

 

$

(0.43)

 

Schedule of potential shares are anti-dilutive and excluded from the weighted average number of shares

 

 

 

 

 

 

 

 

    

December 31, 

 

    

2020

    

2019

    

2018

Warrants

 

2,228,076

 

2,059,128

 

1,674,324

Convertible Debt l

 

 —

 

 —

 

302,976

Convertible Debt 2

 

 —

 

 —

 

827,856